Metabolic syndrome (MetS) affects approximately 20%--25% of the adult population worldwide[@b1]; this multicomponent abnormality includes hyperglycemia, dyslipidemia, abdominal obesity, and hypertension[@b2]. MetS has attracted considerable interest as a risk factor for the development of type 2 diabetes mellitus[@b3] and cancers, such as colorectal cancer[@b4]. A prospective population study identified that men with MetS have a 1.5-fold risk of developing coronary heart disease[@b5].

Systemic low-grade inflammation is responsible for immune function activation and contributes to metabolic disorders[@b6]. Elevated immune globulin A (IgA), IgE, and IgG, but not IgM, are related to myocardial infarction and cardiac death in males with hyperlipidemia[@b7]. High-sensitivity C-reactive protein is an acute-phase response marker and a well-known independent predictor of metabolic dysfunction, such as cardiovascular disease[@b8], hypertensi[@b9][@b10], and diabetes[@b11][@b12]. Similarly, elevated levels of other acute-phase reactants, such as interleukin-6[@b13], and proinflammatory cytokines, such as tumor necrosis factor-α[@b14] and fibrinogen[@b15], can also be risk markers of metabolic diseases. Moreover, insulin resistance (IR)^16^,^17^, obesity[@b18], and hypercholesterolemia[@b19] as components of MetS are usually independently interrelated to an increase in inflammatory markers. Given these findings, low-grade inflammation exerts significant effects on the development of metabolic dysfunction.

The complement system response to inflammation and infection is significant in innate and adaptive immune mechanisms. C3 and C4, mainly produced by the liver[@b20], are the major plasma proteins of the immune system complement pathways[@b21]. Common genetic variants at the C3 locus have been suggested to be associated with risk of MetS and its components[@b22]. A cohort study of 1220 adults from a general population proved that the fasting level of C3 was strongly associated with abdominal obesity and blood pressure[@b23]. C3 is also associated with postprandial triglyceride metabolism, higher homeostasis model assessment of IR (HOMA-IR), and diabetes development[@b24][@b25][@b26]. Furthermore, elevated C3 concentrations show greater predictive value than insulin or C reactive protein for the incidence of fitness and fatness[@b27]. Adipose tissue may be considered as an immunological organ[@b28], and adipose tissue inflammation of obese subjects contributes to the development of IR and metabolic dysfunction[@b29]. High expressions of C3 and C4 are related to adipose tissue variables and involved in the development of visceral adiposity[@b30].

Therefore, the complement system response to inflammation and infection may play an important role in MetS expression. However, to our knowledge, large-scale epidemiological studies that demonstrate the association between C3 and C4, and MetS morbidity are limited. In the present investigation, we conducted a cross-sectional and longitudinal population-based study to elucidate whether C3, C4, or immune globulin concentrations are associated with MetS risk, or predict MetS incidence.

Results
=======

Participants' selection of the study
------------------------------------

[Figure 1](#f1){ref-type="fig"} shows the procedures for selecting participants in the study (n = 4303). Among the 4303 participants aged 17--88 years old, 2376 eligible male participants were selected in the cross-sectional study based on the exclusion criteria. A total of 308 (12.96%) and 2068 subjects diagnosed with MetS and without MetS (non-MetS) were identified, respectively, based on the definition of MetS. After applying the exclusion criteria during the follow-up period, 976 participants were included in the cohort study from the 2068 participants without MetS from 2009 to 2013. After a 4 year follow-up, 166 subjects (17.01%) were diagnosed with MetS.

General characteristics investigation
-------------------------------------

[Table 1](#t1){ref-type="table"} shows the general characteristics of male participants. The C3 and C4 levels of participants with MetS were 15% higher than those without MetS (both *P* \< 0.001). However, no significant differences were observed in IgM (*P* = 0.148), IgA (*P* = 0.115), IgE (*P* = 0.699), and IgG (*P* = 0.269) between the two subjects groups. The smoking status between MetS and non-MetS participants was also not significantly different (*P* = 0.070).

Correlation coefficients between C3 and C4 concentrations and metabolic variables
---------------------------------------------------------------------------------

Pearson's correlation coefficient showed the relationship between the C3 and C4 levels and the risk factors of MetS after adjusting the confounding factors ([Table 2](#t2){ref-type="table"}). C3 levels were significantly positively correlated with body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TRIG), glucose (GLU), and decreased high-density lipoprotein (HDL) (all *P* \< 0.001). C4 levels were also related to the risk parameters except for TRIG (*P* = 0.153) and GLU (*P* = 0.057). In addition, C3 levels were highly correlated with BMI and WC (both R = 0.436), whereas C4 levels were strongly correlated with BMI (R = 0.221). No significant association among IgE, IgG, IgM, IgA, and the components of MetS was found after adjustment of multiple factors ([Supplemental Table 1](#S1){ref-type="supplementary-material"} online).

Association between C3 and C4 levels and MetS in the cross-sectional study
--------------------------------------------------------------------------

[Table 3](#t3){ref-type="table"} presents the association between the concentration quartiles of C3 and C4 and MetS by logistic regression analysis. In the unadjusted model (model 1), the odds radio (ORs) of MetS in the highest quartile of C3 and C4 levels were 6.240 and 2.213, respectively (both *P* \< 0.001). After multi-factor adjustment (model 2), the ORs in the highest quartile of C3 and C4 concentrations were 7.047 (*P*~trend~ \< 0.001) and 1.961(*P*~trend~ = 0.041). Nevertheless, binary logistic regression analysis showed that the ORs and 95% confidence intervals (CIs) of MetS for IgE, IgG, IgM, and IgA were mostly non-significant ([Supplemental Table 2](#S1){ref-type="supplementary-material"} online).

C3 and C4 levels predict MetS incidence in the cohort from 2009 to 2013
-----------------------------------------------------------------------

Relative risks (RRs) for MetS development and the quartiles of C3 and C4 concentrations are shown in the final Cox regression analysis table ([Table 4](#t4){ref-type="table"}). In unadjusted analysis (model 1), the RRs of MetS for the highest quartile of C3 and C4 concentrations were 4.556 and 2.711, respectively (both *P* \< 0.001). After multi-factor adjustment (model 2), the highest C3 concentrations were associated with 4.7 times higher risk of developing MetS compared with their counterparts. Data showed that the incidence of MetS increased with rising quartiles (*P*~trend~ \< 0.001) ([Fig. 2](#f2){ref-type="fig"}). Similarly, the chance of developing MetS was 2.590 times higher in individuals with the highest quartile of C4 concentrations compared with those with the lowest quartile of C4 concentrations (*P* \< 0.001).

Discussion
==========

Both C3 and C4, but not IgE, IgG, IgM, and IgA, were related to independent components of MetS, and elevated C3 or C4 was positively associated with MetS in the cross-sectional study. We also found that the high baseline C3 and C4 levels indicated increased risk of MetS over a 4-year follow-up study.

Chronic inflammation is associated with MetS[@b6]. Meanwhile, the activation of complement system is an important part of inflammatory processes that interferes with normal metabolism and insulin signaling[@b17]. In the present study, baseline C3 and C4 levels, but not IgM, IgA, IgE, and IgG levels, showed significant differences between MetS and non-MetS groups. A previous cross-sectional study reported that a borderline relationship exists between IgM levels and MetS. This finding may be mediated by lipid metabolism disorder in males (*P* = 0.07) when IgM levels are significantly related to elevated TRIG and decreased HDL[@b31]. However, in the present study, the IgM, IgA, IgE, and IgG exhibited no significant effects on MetS and its components among the subjects ([Supplemental Tables 1](#S1){ref-type="supplementary-material"} and [2](#S1){ref-type="supplementary-material"} online). Therefore, we propose that the activation of inflammatory pathways, particularly the complement pathway, mainly affects MetS incidence.

Several investigations, mainly case--control or cross-sectional studies reported consistent results. For example, a case--control study found that C3 concentrations are significantly related to serum TRIG, GLU, and BP levels[@b32]. Individuals with elevated C3 concentrations exhibit three-fold higher risk of MetS compared with those in the bottom 50th percentile, and higher MetS risk among high dietary fat consumers and smokers[@b33]. A cross-sectional study of Prospective Investigation of the Vasculature in Uppsala Seniors study also demonstrated that C3 and C4 are significantly related to the occurrence of MetS in 1016 older people (≥70 years old)[@b29]. By contrast, the current study has a larger sample size and relatively young population, with an average age of 42.6 years old. In a cross-sectional population-based survey of Wamba *et al.*[@b34], they proposed that acylation-stimulating protein, but not complement C3, is associated with MetS components in 1603 Chinese children and adolescents (6--18 years old). In another study of Wamba *et al.* on children aged 2--6 years old, they reported a small but significant increase in plasma C3 in young obese subjects[@b35]. Thus, these results indicate that C3 and C4 may affect MetS prevalence only in adult population, but not significantly in children.

A cohort study focused on cardiometabolic risk and MetS; by analyzing the association between C3 and the incidence of MetS in 265 women and 230 men, the study reported that C3 predicted the risk of MetS in women but not in men[@b23]. However, basing on the results from the present cohort study, we propose that elevated C3 is an independent risk factor for the development of MetS in a large sample of men. This relationship still existed in men, even after adjustment for other confounding factors. Moreover, the present study found that increased C4 is another potential factor in predicting MetS.

The pathogenesis of MetS caused by activation of complement system is not clearly elucidated, and several pathways may explain how complement factors affect MetS. C3 and C4, as the major plasma proteins of the complement pathway, play a crucial role in the immune system[@b21]. High levels of C3 may cause high C3a and C5a, these anaphylatoxins mediate inflammatory processes by acting on their respective receptors (C3aR and C5aR)[@b36][@b37]. *In vivo*, studies showed that C3aR and C5aR knock-out mice present reduced macrophage infiltration and improved insulin sensitivity[@b32][@b37][@b38]. C3a and C5a function as hormones that have insulin-like effects on 3T3-L1 adipocytes through increasing glucose and fatty acid uptake while inhibiting cAMP transmission and lipolysis to promote energy conservation[@b39]. In addition, C3a-desArg is a degraded product of C3 and can stimulate lipogenesis in adipose cells and triglyceride synthesis[@b40][@b41], and also promote islets secreting glucose-dependent insulin[@b38][@b42]. The metabolism of triglyceride was accelerated with increasing C3a-desArg levels. This phenomenon increased the plasma triglyceride levels, thereby explaining the IR in obese people and MetS[@b29]. Zhou *et al.* suggested that C3 was involved in mediating epithelial-to-mesenchymal transition and in activating intrarenal RA systems with the influence of renin generation. The finding indicated that high level C3 could increase intrarenal Ang II concentration and BP levels[@b43], which could explain the association between C3 and hypertension.

The present work is the first to combine cross-sectional and longitudinal studies to investigate the casual relationship between complement activation and MetS. The strengths of our study include population-based sample, large sample size, and relatively high response rate, which may improve the credibility of the results.

Nevertheless, several limitations should be highlighted. First, this study was conducted only among adult males. The results may lack sufficient evidence to indicate the relationships in children and females. Second, no diet intake data or detailed lifestyles were investigated. Therefore, the effects of diet on MetS were not analyzed in our study.

In conclusion, activation of complement factors, as an important part of inflammatory processes, may directly affect MetS incidence. Elevated C3 and C4 levels were independent risk factors for the development of MetS in Chinese male population. Further studies are urgently needed to explore the molecular mechanisms of activation of complement factors acting on MetS.

Materials and Methods
=====================

Study population
----------------

This study is part of Fangchenggang Area Males Health and Examination Survey (FAMHES). FAMHES is a population-based epidemiological cohort study performed in Guangxi, China[@b44]. A total of 4303 eligible Chinese men aged 17 to 88 years completed face-to-face interview and physical examination from September 2009 to December 2009 at the Medical Centre of Fangchenggang First People's Hospital.

### Ethics

This study was approved by the Ethics and Human Subject Committee of Guangxi Medical University and was conducted in accordance with the Declaration of Helsinki. All participants were given and signed a written informed consent form prior to the study.

Cross-sectional study
---------------------

The exclusion criteria are as follows:[@b1] presence of hepatic disease (ALT \> 2.0 times upper limit of normal or chronic hepatitis or liver cirrhosis), [@b2]presence of renal disease (creatinine \>178 μmol/l), [@b3]missing data on C3 and C4 concentrations, [@b4]taking anti-inflammatory medication, and[@b5] clinical history of hyperthyroidism, rheumatoid arthritis, and cancer. Participants who had signs of high fasting blood glucose levels and high BP at the initial assessment were included in the study. Among the 4303 participants, 2376 with complete data were included in the cross-sectional study in 2009.

Cohort study
------------

A total of 2376 participants without MetS at baseline in 2009 were followed up for 4 years. The participants completed the same face-to-face interview and physical examination in 2013. We excluded members who had one or more of the following criteria:[@b1] loss to follow-up, [@b2]unwillingness to participate, [@b3]subsequent diseases that are unsuitable for participation, and[@b4] missing data on anthropometric measurements or clinical biochemistry assays in 2013. A total of 976 men participated in the follow-up exam.

Data collection
---------------

We collected the data from Fangchenggang First People's Hospital Medical Examination Center. Participants' age, smoking habits, alcohol consumption, and health status were obtained through a face-to-face interview. Subjects who had ever smoked cigarettes for six months or longer were classified as smokers, and others were considered as non-smokers. Drinkers were defined according to alcohol consumption once or more a week, and others were considered as non-drinkers. Subjects who had exercised two hours or more each week were classified as regular physical activity, and otherwise subjects were classified as irregular physical activity[@b45]. Participants were considered to have a family history of chronic diseases if one of the following is present in participants' parents or siblings: hypertension, type 2 diabetes mellitus, coronary heart disease, and stroke[@b46].

Anthropometric measurements were conducted by trained personnel using a standard protocol. Standing heights were measured using a vertical telescopic stadiometer with a horizon headboard on the top to the nearest 0.1 cm. Participants were weighed without shoes to the nearest 0.1 kg. BMI was calculated as weight divided by height squared (kg m^−2^). WC was assessed midway between the lower rib margin and the iliac. BP was measured twice on each visit after 5 min of rest with an oscillometric precision blood pressure instrument on the right arm by trained nurses.

Laboratory measurements
-----------------------

Overnight fasting venous blood samples were obtained between 8 a.m. and 10 a.m. The samples were transported on ice in an upward position to the testing center of the Department of Clinical Laboratory at the First Affiliated Hospital of Guangxi Medical University in Nanning within 2 h. Sera were separated using a centrifuge within 15--25 min and stored at −80 °C until analysis. Blood lipids and serum glucose were determined using the enzymatic assay on a Dimension-RxL chemistry analyzer (Dade Behring, USA). IgE was measured by electro-chemiluminescence immunoassay on COBAS 6000 system E601 (Elecsys module) immunoassay analyzers (Roche Diagnostics, IN, Germany) with the same batch of reagents. C3, C4, IgG, IgA, and IgM were measured with a Hitachi 7600 autoanalyzer (Hitachi Corp., Japan) in the testing center of the First Affiliated Hospital of Guangxi Medical University. The coefficients of variation were 2.16% for C3, 2.51% for C4, 4.67% for IgM, 4.97% for IgG, 3.57% for IgA, and 3.3% for IgE.

Definition of MetS cases
------------------------

Based on the National Cholesterol Education Program -- Adult Treatment Panel III definition as modified by the American Heart Association/National Heart, Lung and Blood Institute[@b41], individuals with MetS were identified having arbitrarily three or more of the following criteria: (1) WC ≥ 90 cm, (2) TRIG ≥ 1.7 mmol/l, (3) HDL \< 1.03 mmol/l, (4) SBP ≥ 130 mmHg/DBP ≥ 85 mmHg or current use of hypotensive drugs or have a history of hypertension, and (5) fasting GLU ≥ 5.6 mmol/l or previously diagnosed with type 2 diabetes mellitus or taking medications to control hyperglycemia.

Statistical methods
-------------------

Continuous variables were described as mean and standard deviation (SD) ranges with normal distribution, median, and 25--75 percentile with abnormal distribution, and categorical variables were described as proportions. Two-sided *t* test and Mann--Whitney U test were used to analyze the differences of variables between the MetS and normal groups. Pearson's coefficient was employed to describe the correlations of C3 and C4 with metabolic variables after multi-factor adjustment (including age, smoking, drinking status, physical activity, and family history of chronic diseases). Estimates of the likelihood of MetS and 95% CIs were obtained using logistic regression analysis in models with or without adjustment of multi-factors. After the 4-year follow-up, Cox proportional hazard regression was conducted to compute RRs and 95% CI for MetS after adjustment or without adjustment for multi-factors. A linear trend across increasing quartiles was tested with a mean value of each quartile as an ordinal variable. All statistical analyses were performed using SPSS (Chicago, IL, USA) for Windows 16.0. Statistical tests were two-sided, and *P* \< 0.05 was considered statistically significant.
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![Flow chart for selection of study participants.\
Based on the inclusion criteria, 2376 males participated in the cross-sectional study and 976 males participated in the cohort study.](srep18713-f1){#f1}

![RRs of MetS presence in 2013 according to the quartiles of C3 and C4 baseline levels from 2009.\
RRs exhibited an increasing trend when the quartiles of C3 and C4 increased (*p* \< 0.001).](srep18713-f2){#f2}

###### General characteristics of study population stratified for the MetS and non-MetS in 2009 (n = 2376).

  Variable                                             MetS (n = 308)        Non-MetS (n = 2068)      *P*
  ----------------------------------------------- ------------------------ ------------------------ -------
  Age (years)                                          42.59 ± 10.47            37.11 ± 10.99        0.000
  BMI (kg/m^2^)                                         27.10 ± 3.10             22.76 ± 3.00           
  WC (cm)                                               92.18 ± 7.22             79.16 ± 8.29           
  SBP (mmHg)                                           131.78 ± 17.18           116.31 ± 14.13          
  DBP (mmHg)                                           86.22 ± 11.49             75.67 ± 9.20           
  TRIG (mmol/l)                                       2.50 (1.88,3.68)         1.03 (0.74,1.49)         
  HDL (mmol/l)                                          1.28 ± 0.49              1.42 ± 0.30            
  GLU (mmol/l)                                          6.13 ± 1.71              5.20 ± 0.75            
  C3 (g/l)                                              1.25 ± 0.22              1.10 ± 0.22         0.000
  C4 (g/l)                                              0.36 ± 0.09              0.33 ± 0.10         0.000
  IgM (g/l)                                             1.39 ± 0.77              1.44 ± 0.77         0.148
  IgA (g/l)                                             2.61 ± 1.06              2.47 ± 0.89         0.115
  IgE (g/l)                                        128.65 (51.84, 290.75)   127.25 (52.01, 324.40)   0.699
  IgG (g/l)                                             13.20 ± 2.77             13.43 ± 2.63        0.269
  Smoking status, smokers, n (%)                         174(56.5%)               1054(51%)          0.070
  Alcohol consumption, drinkers, n (%)                   144(46.8%)               813(39.3%)         0.013
  Physical activity, physically active, n (%)            90(29.2%)                489(23.6%)         0.034
  Family history of chronic disease, yes, n (%)          86(27.9%)                392(19.0%)         0.000

Data are presented as mean ± standard deviation (SD), and median (25 percentile, 75 percentile) or counts (percent).

Two-sided *t* test for categorical variables and Mann--Whitney U test for continuous variables.

MetS, metabolic syndrome; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; TRIG, triglycerides; HDL, high-density lipoprotein cholesterol; GLU, glucose; C3, complement factor 3; C4, complement factor 4; IgM, immune globulin M; IgA, immune globulin A; IgE, immune globulin E; IgG, immune globulin G.

###### Correlation coefficients and significance of association between serum C3 and C4 and metabolic variables after multi-factors adjustment.

  Variable      C3      C4             
  ---------- -------- ------- -------- -------
  BMI         0.436    0.000   0.221    0.000
  WC          0.436    0.000   0.218    0.000
  SBP         0.146    0.000   0.078    0.000
  DBP         0.186    0.000   0.077    0.000
  TRIG        0.128    0.000   0.029    0.153
  HDL         −0.239   0.000   −0.146   0.000
  GLU         0.108    0.000   0.039    0.057

Multi-factors: age, alcohol drinking status, smoking status, physical activity, and family history of chronic diseases.

Abbreviation: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TRIG, triglycerides; HDL, high density lipoprotein cholesterol; GLU, glucose; C3, complement factor 3; C4, complement factor 4.

###### Odds ratios and 95% CI for MetS according to the C3 and C4 concentrations in 2009: a binary logistic regression.

                                               Total           MetS           Model 1 OR (95%CI)          *P*~1~           Model 2 OR (95%CI)   *P*~2~
  ----------------------- ------------------- ------- ---------------------- -------------------- ----------------------- -------------------- --------
  C3                      Q1 ( ≤ 0.967 g/l)     595             32                  1.000                                        1.000             
  Q2 (0.968--1.104 g/l)   593                   38     1.205 (0.742, 1.956)         0.452          1.413 (0.863, 2.313)          0.169         
  Q3 (1.105--1.263 g/l)   596                   83     2.847 (1.861, 4.354)         0.000          2.982 (1.934, 4.598)          0.000         
  Q4 ( ≥ 1.264 g/l)       592                   155    6.240 (4.181, 9.315)         0.000          7.047 (4.664, 10.648)         0.000         
  *P*~*trend*~                                                0.000                                        0.000                               
  C4                      Q1 ( ≤ 0.269 g/l)     598             48                  1.000                                        1.000             
  Q2 (0.270--0.322 g/l)   596                   65     1.403 (0.948, 2.075)         0.090          1.273 (0.855, 1.896)          0.235         
  Q3 (0.323--0.382 g/l)   589                   99     2.315 (1.606, 3.337)         0.000          2.017 (1.389, 2.928)          0.000         
  Q4 ( ≥ 0.383 g/l)       593                   96     2.213 (1.533, 3.195)         0.000          1.961 (1.349, 2.849)          0.000         
  *P*~*trend*~                                                0.035                                        0.041                               

Abbreviation: OR, odds ratio; CI, confidence interval; Q, quartile; C3, complement factor 3; C4, complement factor 4.

Model 1 was not adjusted.

Model 2 was adjusted for age, smoking status, alcohol drinking status, family history of chronic disease, and physical activity.

###### RRs and 95% CI for MetS incidence in 2013 using the baseline levels of C3 and C4 from 2009: a Cox regression analysis.

                                               Total           MetS           Model 1          *P*~1~          Model 2   *P*~2~
  ----------------------- ------------------- ------- ---------------------- --------- ---------------------- --------- --------
  C3                       Q1 ( ≤ 0.955 g/l)    244             18             1.000                            1.000       
  Q2 (0.966--1.103 g/l)           246           21     1.157 (0.617, 2.172)    0.649    1.249 (0.663, 2.354)    0.491   
  Q3 (1.104--1.266 g/l)           242           45     2.521 (1.459, 4.354)    0.001    2.522 (1.459, 4.361)    0.001   
  Q4 ( ≥ 1.267 g/l)               244           82     4.556 (2.735, 7.588)    0.000    4.779 (2.854, 8.003)    0.000   
  *P*~*trend*~                                                0.000                            0.000                    
  C4                       Q1 ( ≤ 0.273 g/l)    246             21             1.000                            1.000       
  Q2 (0.274--0.324 g/l)           243           37     1.784 (1.044, 3.047)    0.034    1.670 (0.975, 2.862)    0.062   
  Q3 (0.325--0.385 g/l)           245           52     2.486 (1.498, 4.127)    0.000    2.309 (1.386, 3.845)    0.001   
  Q4 ( ≥ 0.386 g/l)               242           56     2.711 (1.642, 4.476)    0.000    2.590 (1.567, 4.280)    0.000   
  *P*~*trend*~                                                0.000                            0.000                    

Abbreviation: RR, relative risk; CI, confidence interval; Q, quartile; C3, complement factor 3; C4, complement factor 4.

C3 and C4 were respectively divided into 4 grades according to their interquartile range at baseline.

Model 1 was not adjusted.

Model 2 was adjusted for age, smoking status, alcohol drinking status, family history of chronic disease, and physical activity.
